<?xml version="1.0" encoding="UTF-8"?>
<p>Radiation therapy during a pandemic has unique challenges; unlike medical or surgical therapies, radiotherapy patients need to attend daily and the nature of the treatment is such that an interruption of therapy is clinically unacceptable. Even if no new cases are started, the patients currently on treatment must continue 
 <xref rid="onco13306-bib-0022" ref-type="ref">22</xref>. Patients who are at risk or who are a known contact should be seen and treated in a separate room. This is possible in the outpatient clinic setting or even in operating suites; however, radiotherapy treatment requires facilities that are unique and limited. There may not be excess capacity to have a linac, simulator, or mould room specifically set aside for at‐risk patients. Concerns that SARS‐CoV‐2 particles might remain viable for up to 72 hours have implications for subsequent patient and staff activity in that room 
 <xref rid="onco13306-bib-0022" ref-type="ref">22</xref>, 
 <xref rid="onco13306-bib-0044" ref-type="ref">44</xref>. The American Society for Radiation Oncology (ASTRO) recently published brief guidelines for COVID‐19 recommendations to radiation oncology practices 
 <xref rid="onco13306-bib-0045" ref-type="ref">45</xref>.
</p>
